Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View Item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.

Thumbnail
View/Open
Published version (2.203Mb)
Publication Date
2016-04
ICR Author
Buus, Richard
Author
Chikh, A
Ferro, R
Abbott, JJ
Piñeiro, R
Buus, R
Iezzi, M
Ricci, F
Bergamaschi, D
Ostano, P
Chiorino, G
Lattanzio, R
Broggini, M
Piantelli, M
Maffucci, T
Falasca, M
Type
Journal Article
Metadata
Show full item record
Abstract
It is now well established that the enzymes phosphoinositide 3-kinases (PI3Ks) have a key role in the development and progression of many cancer types and indeed PI3Ks inhibitors are currently being tested in clinical trials. Although eight distinct PI3K isoforms exist, grouped into three classes, most of the evidence currently available are focused on one specific isoform with very little known about the potential role of the other members of this family in cancer. Here we demonstrate that the class II enzyme PI3K-C2β is overexpressed in several human breast cancer cell lines and in human breast cancer specimens. Our data indicate that PI3K-C2β regulates breast cancer cell growth in vitro and in vivo and that PI3K-C2β expression in breast tissues is correlated with the proliferative status of the tumor. Specifically we show that downregulation of PI3K-C2β in breast cancer cell lines reduces colony formation, induces cell cycle arrest and inhibits tumor growth, in particular in an estrogen-dependent in vivo xenograft. Investigation of the mechanism of the PI3K-C2β-dependent regulation of cell cycle progression and cell growth revealed that PI3K-C2β regulates cyclin B1 protein levels through modulation of microRNA miR-449a levels. Our data further demonstrate that downregulation of PI3K-C2β inhibits breast cancer cell invasion in vitro and breast cancer metastasis in vivo. Consistent with this, PI3K-C2β is highly expressed in lymph-nodes metastases compared to matching primary tumors. These data demonstrate that PI3K-C2β plays a pivotal role in breast cancer progression and in metastasis development. Our data indicate that PI3K-C2β may represent a key molecular switch that regulates a rate-limiting step in breast tumor progression and therefore it may be targeted to limit breast cancer spread.
URL
https://repository.icr.ac.uk/handle/internal/90
Collections
  • Other ICR Research
Licenseref URL
https://creativecommons.org/licenses/by/4.0
Version of record
10.18632/oncotarget.7761
Subject
Cell Line, Tumor
Animals
Humans
Mice
Mice, Nude
Breast Neoplasms
Disease Progression
Signal Transduction
Cell Proliferation
Female
Class II Phosphatidylinositol 3-Kinases
MCF-7 Cells
Heterografts
Language
eng
Date accepted
2016-02-11
License start date
2016-04
Citation
Oncotarget, 2016, 7 (14), pp. 18325 - 18345

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.